Clinical trials: Relapsed Ovarian Cancer
Ovarian Epithelial Cancer, Fallopian Tube Cancer
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
This is a Phase 1, open-label, dose-escalation ,and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary…
- Conditions
- Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04029909
- Testing
- Gimatecan 0.6mg/m2/d, 0.8mg/m2/d, 0.4mg/m2/d
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Lee's Pharmaceutical Limited
Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
This is a prospective, open-label, single arm, multi-centre interventional study to assess the clinical efficacy and safety of olaparib maintenance monotherapy and will be conducted in patients with platinum sensitive relapsed…
- Conditions
- Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive
- Trial name
- L-MOCA (NCT03534453)
- Testing
- Olaparib 300mg tablets
- Where
- 25 sites in China, Malaysia
- Volunteers
- 229 people
- Sponsor
- AstraZeneca
Recurrent Ovarian Cancer
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
This study is a multicenter, open-label Phase Ib/II clinical trial to observe and evaluate the safety, tolerability and pharmacokinetics of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer…
- Trial name
- NCT06308406
- Testing
- Bevacizumab； HRS-1167
- Where
- 18 sites in China
- Volunteers
- 54 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
A Study to Investigate LYL797 in Adults With Solid Tumors
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC)…
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05274451
- Testing
- LYL797
- Where
- 18 sites in United States
- Volunteers
- 57 people
- Sponsor
- Lyell Immunopharma, Inc.
Ovarian Neoplasm
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal…
- Trial name
- COHORT-A (NCT05751629)
- Testing
- Dostarlimab, Bevacizumab, Niraparib
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Tesaro, Inc.
Non-Germline BRCA Mutated Ovarian Cancer
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
The purpose of the study is to assess the efficacy and safety of single-agent olaparib as a maintenance treatment in patients with relapsed High Grade Serous Ovarian Cancer (including patients with primary peritoneal and/or…
- Trial name
- OPINION (NCT03402841)
- Testing
- Olaparib
- Where
- 91 sites in Austria, Belgium and 17 more
- Volunteers
- 279 people
- Sponsor
- AstraZeneca
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Ovarian Cancer
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
- Trial name
- NCT02537444
- Testing
- Acalabrutinib, acalabrutinib and pembrolizumab combination
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Acerta Pharma BV
Ovarian Neoplasms, Ovarian Cancer
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens.
- Trial name
- QUADRA (NCT02354586)
- Testing
- Niraparib
- Where
- 55 sites in United States, Canada
- Volunteers
- 463 people
- Sponsor
- Tesaro, Inc.
Advanced/Recurrent Ovarian Cancer
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
The main purpose of this study is to investigate the safety, tolerability, preliminary efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of biomarker-guided novel anticancer agent(s) as monotherapy or combination therapy…
- Trial name
- NCT07060365
- Testing
- Saruparib
- Where
- Spain
- Sponsor
- AstraZeneca
Ovarian Cancer, Relapsed or Refractory
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent…
- Conditions
- Ovarian Cancer, Relapsed or Refractory, Chiauranib, Paclitaxel
- Trial name
- CHIPRO (NCT04921527)
- Testing
- chiauranib, Paclitaxel
- Where
- China
- Volunteers
- 454 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Advanced Solid Tumors, Ovarian Cancer
A Study of PHST001 in Advanced Solid Tumors
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination…
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
- Trial name
- NCT06840886
- Testing
- PHST001, Paclitaxel, Topotecan
- Where
- 20 sites in United States
- Volunteers
- 426 people
- Sponsor
- Pheast Therapeutics
Ovarian Cancer
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.
- Trial name
- NCT00082212
- Testing
- Cetuximab
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer Recurrent
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs.
- Trial name
- NCT06014528
- Testing
- IN10018, Pegylated Liposomal Doxorubicin
- Where
- China
- Volunteers
- 168 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
This study is a multicenter, randomized, controlled, open-label, phase II study to evaluate the efficacy and safety of SG001 in combination with doxorubicin hydrochloride liposome injection in patients with platinum-resistant…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT04983550
- Testing
- SG001, Doxorubicin hydrochloride liposome injection
- Volunteers
- 126 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ovarian Neoplasms
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
- Trial name
- NCT00046800
- Testing
- OSI-211 (Liposomal Lurtotecan)
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 80 people
- Sponsor
- Astellas Pharma Inc
Solid Tumor, Gastric Cancer
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
This clinical study is to investigate the safety and tolerability of CCT303-406 CAR modified autologous T cells (CCT303-406) in subjects with relapsed or refractory stage IV metastatic HER2-positive solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT04511871
- Testing
- CCT303-406
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study LY2228820 for Recurrent Ovarian Cancer
A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01663857
- Testing
- LY2228820, Carboplatin, Gemcitabine
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 118 people
- Sponsor
- Eli Lilly and Company
Ovarian Epithelial Cancer, Fallopian Tube Cancer
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
The study objective is to investigate the efficacy and safety of p53 combined with chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.
- Conditions
- Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02435186
- Testing
- p53 gene, Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Ovarian Cancer
Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer
This clinical trial will evaluate the efficacy and safety of chiauranib added to chemotherapy in patients with relapsed or refractory ovarian cancer, in the meantime, explore the pharmacokinetics characteristic after the combined…
- Trial name
- NCT03901118
- Testing
- chiauranib, etoposide, paclitaxel
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Chipscreen Biosciences, Ltd.